UPDATE: JPMorgan Downgrades Orchard Therapeutics (ORTX) to Underweight on Lack of Meaningful Short-term Catalysts and Negative Sentiment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to UPDATE: JPMorgan Downgrades Orchard Therapeutics (ORTX) to Underweight on Lack of Meaningful Short-term Catalysts and Negative Sentiment

Aruvant Appoints Moya Daniels as Senior Vice President of Regulatory Affairs and Quality Assurance

November 15, 2021 4:02 PM EST

NEW YORK and BASEL, Switzerland, Nov. 15, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced the appointment of Moya M. Daniels as senior vice president (SVP) of regulatory affairs and quality assurance (QA), effective immediately. Ms. Daniels brings over thirty years of regulatory, quality and clinical experience in the biopharmaceutical industry. 

"Given her regulatory and QA expertise, particularly in the cell and gene therapy space, Moya will play a key role in helping to bring our investigational gene therapies through the FDA review process and ultimately to... More